Immediate Access to Opioid Agonists Found Cost-Effective

Share this content:
Immediate Access to Opioid Agonists Found Cost-Effective
Immediate Access to Opioid Agonists Found Cost-Effective

WEDNESDAY, Nov. 22, 2017 (HealthDay News) -- Immediate access to opioid agonist treatment (OAT) for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care, according to a study published online Nov. 21 in the Annals of Internal Medicine.

Emanuel Krebs, from St. Paul's Hospital in Vancouver, Canada, and colleagues sought to determine the cost-effectiveness of OAT versus observed standard of care for patients presenting with opioid use disorder. Population-level administrative databases capturing treatment and criminal justice records for California were linked (2006 to 2010).

Immediate access to OAT for all treatment recipients was found by the researchers to cost less (by $78,257), with patients accumulating more quality-adjusted life-years (by 0.42) versus the observed standard of care. Imagining a hypothetical scenario where all Californians starting treatment of opioid use disorder in 2014 had immediate access to OAT, the team found that total lifetime savings for this cohort could be as high as $3.8 billion.

"The value of publicly funded treatment of opioid use disorder in California is maximized when OAT is delivered to all patients presenting for treatment, providing greater health benefits and cost savings than the observed standard of care," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »